VIS 954
Alternative Names: VIS-954Latest Information Update: 04 Oct 2024
Price :
$50 *
At a glance
- Originator Visterra
- Class Monoclonal antibodies
- Mechanism of Action Complement C5a receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Autoimmune disorders
Most Recent Events
- 22 Jul 2024 Visterra completes a phase-I trial in Autoimmune disorders (In volunteers) in USA (SC, Injection) (NCT06212804)
- 22 Nov 2023 Phase-I clinical trials in Autoimmune disorders (In volunteers) in USA (SC) (NCT06212804)
- 27 Sep 2022 Preclinical trials in Autoimmune disorders in USA (SC) (Visterra website, September 2022)